OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights

World News: . []

REDWOOD CITY, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (“OncoMed”) (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its board of directors declared a one-time special dividend in the form of a contractual right to receive, on a pro rata basis, cash payments from OncoMed upon the actual receipt by OncoMed or its affiliates of certain contingent cash amounts in the future following the exercise by Celgene Corporation or certain of Celgene Corporation’s affiliates (together, “Celgene”) of the exclusive option granted by OncoMed to Celgene in relation to OncoMed’s etigilimab product. More specifically, if a specified approval or sales milestone is achieved or if royalties are paid by Celgene to OncoMed or its affiliates in respect of the etigilimab product (in each case, pursuant to a license agreement to be entered into by OncoMed and Celgene upon Celgene’s exercise of its exclusive option in relation to OncoMed’s etigilimab product (the “TIGIT License Agreement”)), the special dividend will entitle stockholders to receive an amount in cash equal to such holder’s pro rata portion of any cash payments made by Celgene and actually received by OncoMed or its affiliates in respect thereof, net of any tax and reasonable costs and expenses incurred by OncoMed or its affiliates in connection with such payments.

All payments will be made to stockholders of record as of the close of business on April 5, 2019. The special dividend will be distributed as of the close of business on April 5, 2019. In the event that OncoMed receives no payment amounts under the TIGIT License Agreement, OncoMed stockholders will not receive any cash payments pursuant to this special dividend. There can be no assurance that any of the applicable milestones and royalties under the TIGIT License Agreement will be achieved or that any stockholders will receive payments.

Alexandra Santos

More news and information about OncoMed Pharmaceuticals, Inc.

Published By:

Globe Newswire: 11:00 GMT Friday 15th March 2019

Published: .

Search for other references to "oncomed" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us